FDA approves new breast cancer drug

March 14, 2007 18:15


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

The Israel Cancer Association (ICA) welcomed the US Food and Drug Administration announcement Wednesday that it had granted approval for the marketing of Tykerb, a drug for women with metastatic breast cancer that no longer responds to Herceptin. The FDA examined studies showing that when Tykerb (of GlaxoSmithKline) is given along with the drug Xeloda, another breast cancer drug from Roche Pharmaceuticals, the disease is kept under control better than with Xeloda alone. Tykerb is not in Israel's basket of health services, but it will probably be proposed for inclusion next year. The ICA said Tykerb, which prevents further decline of cancer in women with metastases, is yet another tool to fight common malignancies and to raise the recovery rate.

Related Content

[illustrative photo]
September 24, 2011
Diabetes may significantly increase risk of dementia